SMT201700080B - Agente terapeutico per malattia basato sull’effetto di inibizione del fattore inibitore della migrazione dei macrofagi - Google Patents

Agente terapeutico per malattia basato sull’effetto di inibizione del fattore inibitore della migrazione dei macrofagi

Info

Publication number
SMT201700080B
SMT201700080B SM201700080T SM201700080T SMT201700080B SM T201700080 B SMT201700080 B SM T201700080B SM 201700080 T SM201700080 T SM 201700080T SM 201700080 T SM201700080 T SM 201700080T SM T201700080 B SMT201700080 B SM T201700080B
Authority
SM
San Marino
Prior art keywords
macrophages
inhibition
effect
therapeutic agent
disease based
Prior art date
Application number
SM201700080T
Other languages
English (en)
Inventor
Keiichi Tanaka
Kimiko Morimoto
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of SMT201700080B publication Critical patent/SMT201700080B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201700080T 2013-07-18 2017-02-03 Agente terapeutico per malattia basato sull’effetto di inibizione del fattore inibitore della migrazione dei macrofagi SMT201700080B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013149690 2013-07-18

Publications (1)

Publication Number Publication Date
SMT201700080B true SMT201700080B (it) 2017-03-08

Family

ID=52346269

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20170080T SMT201700080T1 (it) 2013-07-18 2014-07-17 Agente terapeutico per malattia basato sull’effetto di inibizione del fattore inibitore della migrazione dei macrofagi
SM20170606T SMT201700606T1 (it) 2013-07-18 2014-07-17 Agente terapeutico per malattia basato sull'effetto di inibizione del fattore inibitore della migrazione dei macrofagi
SM201700080T SMT201700080B (it) 2013-07-18 2017-02-03 Agente terapeutico per malattia basato sull’effetto di inibizione del fattore inibitore della migrazione dei macrofagi

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SM20170080T SMT201700080T1 (it) 2013-07-18 2014-07-17 Agente terapeutico per malattia basato sull’effetto di inibizione del fattore inibitore della migrazione dei macrofagi
SM20170606T SMT201700606T1 (it) 2013-07-18 2014-07-17 Agente terapeutico per malattia basato sull'effetto di inibizione del fattore inibitore della migrazione dei macrofagi

Country Status (22)

Country Link
US (3) US20150353519A1 (it)
EP (2) EP3078372B1 (it)
JP (2) JP5802868B2 (it)
CN (1) CN105407887B (it)
AU (1) AU2014291149B2 (it)
CA (1) CA2918325C (it)
CY (2) CY1118140T1 (it)
DK (2) DK2929880T3 (it)
ES (2) ES2642440T3 (it)
HR (2) HRP20161317T1 (it)
HU (2) HUE029800T2 (it)
IL (1) IL243550B (it)
LT (2) LT2929880T (it)
NO (1) NO3078372T3 (it)
PL (2) PL2929880T3 (it)
PT (2) PT3078372T (it)
RS (2) RS56489B1 (it)
RU (2) RU2750540C2 (it)
SI (2) SI3078372T1 (it)
SM (3) SMT201700080T1 (it)
TW (1) TWI603965B (it)
WO (1) WO2015008827A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6901571B2 (ja) * 2017-01-26 2021-07-14 四川瀛瑞医薬科技有限公司Sichuan Yingrui Pharmaceutical Technology Company ナノ炭素−鉄複合システム及びその組成物、調製方法並びに使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
EP0695547B1 (en) 1993-04-09 2001-08-08 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
EP0868598B1 (de) * 1995-12-21 1999-10-27 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
RU2611341C2 (ru) 2011-08-30 2017-02-21 Тояма Кемикал Ко., Лтд. Способ увеличения эффективности терапии аутоиммунных заболеваний, таких как ревматоидный артрит

Also Published As

Publication number Publication date
PL3078372T3 (pl) 2018-02-28
DK2929880T3 (da) 2017-01-02
RS56489B1 (sr) 2018-01-31
EP3078372B1 (en) 2017-09-13
SMT201700080T1 (it) 2017-03-08
US20160228406A1 (en) 2016-08-11
CN105407887A (zh) 2016-03-16
EP2929880B1 (en) 2016-09-14
US20160228404A1 (en) 2016-08-11
RS55394B1 (sr) 2017-04-28
LT2929880T (lt) 2016-11-25
CY1119496T1 (el) 2018-03-07
WO2015008827A1 (ja) 2015-01-22
SI2929880T1 (sl) 2016-12-30
TWI603965B (zh) 2017-11-01
EP2929880A4 (en) 2015-10-14
NO3078372T3 (it) 2018-02-10
IL243550A0 (en) 2016-02-29
EP2929880A1 (en) 2015-10-14
ES2642440T3 (es) 2017-11-16
ES2593527T3 (es) 2016-12-09
EP3078372A1 (en) 2016-10-12
SMT201700606T1 (it) 2018-01-11
CA2918325A1 (en) 2015-01-22
AU2014291149B2 (en) 2017-05-04
RU2641301C2 (ru) 2018-01-17
RU2016105141A (ru) 2017-08-23
HUE029800T2 (en) 2017-04-28
RU2017131951A (ru) 2019-02-06
JP2016034953A (ja) 2016-03-17
PL2929880T3 (pl) 2017-03-31
JP6060231B2 (ja) 2017-01-11
LT3078372T (lt) 2017-11-27
PT2929880T (pt) 2016-11-08
US20150353519A1 (en) 2015-12-10
AU2014291149A1 (en) 2016-02-11
HK1222556A1 (zh) 2017-07-07
RU2017131951A3 (it) 2020-12-18
HUE034661T2 (en) 2018-02-28
JP5802868B2 (ja) 2015-11-04
HRP20161317T1 (hr) 2016-12-16
TW201536764A (zh) 2015-10-01
CA2918325C (en) 2018-06-26
PT3078372T (pt) 2017-10-18
DK3078372T3 (en) 2017-10-16
SI3078372T1 (en) 2018-01-31
CN105407887B (zh) 2018-09-04
CY1118140T1 (el) 2017-06-28
RU2750540C2 (ru) 2021-06-29
JPWO2015008827A1 (ja) 2017-03-02
IL243550B (en) 2019-06-30
HRP20171497T1 (hr) 2017-11-17
US9918963B2 (en) 2018-03-20

Similar Documents

Publication Publication Date Title
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
CY2021007I2 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
IL268340A (en) Glucosylceramide synthase inhibitors for the treatment of diseases
CY2025015I2 (el) Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου
IL243976B (en) kdm1a inhibitors for disease treatment
EP3019491A4 (en) KINASEHEMMER FOR THE TREATMENT OF DISEASES
HUE053115T2 (hu) Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PL3140097T3 (pl) Korpus wielowarstwowy i sposób jego wytwarzania
HUE040434T2 (hu) Szelektív CDK4/6 inhibitor szilárd alakjai
HUE039899T2 (hu) Bardoxolon-metil 2,2-difluorpropionamid-származékai, ennek polimorf formái és eljárások ezek alkalmazására
HUE053322T2 (hu) Eljárás PI3K/AKT/mTOR inhibitor terápiás hatékonyságának elõrejelzésére PHLDA1 vagy PIK3C2B expressziója alapján
HUE042763T2 (hu) Módosított szerpinek vérzési rendellenességek kezelésére
EP3458123C0 (en) DYNAMIC CATHETER TIP OCCLUSION
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
HRP20181799T1 (hr) Optimizirana farmaceutska formula, namijenjena liječenju upalnih promjena jednjaka
HRP20181554T4 (hr) Tauroursodezoksikolna kiselina (tudca), namijenjena upotrebi u liječenju neurodegenerativnih poremećaja
EP2986120A4 (en) METHYLTRANSFERASE HEMMER FOR THE TREATMENT OF CANCER
IL242355B (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
HUE045192T2 (hu) 6-morfolinil-2-pirazolil-9H-purin származékok és felhasználásuk PI3K inhibitorokként
SI2986325T1 (sl) Postopki zdravljenja motenj ciklusa sečnine
EP2979720A4 (en) MEDICAL TUBUS
SMT201700072B (it) Utilizzo del pidotimod per il trattamento della psoriasi
SMT201700080B (it) Agente terapeutico per malattia basato sull’effetto di inibizione del fattore inibitore della migrazione dei macrofagi